Compare CLH & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLH | NBIX |
|---|---|---|
| Founded | 1980 | 1992 |
| Country | United States | United States |
| Employees | 22591 | N/A |
| Industry | Environmental Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9B | 15.5B |
| IPO Year | 1994 | 1996 |
| Metric | CLH | NBIX |
|---|---|---|
| Price | $317.91 | $137.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 29 |
| Target Price | ★ $361.00 | $206.81 |
| AVG Volume (30 Days) | 349.2K | ★ 1.3M |
| Earning Date | 10-28-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | 1.19 | ★ 3.30 |
| Revenue | ★ $2,944,978,000.00 | $161,626,000.00 |
| Revenue This Year | $9.31 | $36.39 |
| Revenue Next Year | $5.89 | $16.93 |
| P/E Ratio | $267.75 | ★ $41.17 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $201.34 | $122.14 |
| 52 Week High | $335.94 | $186.12 |
| Indicator | CLH | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 54.29 | 36.39 |
| Support Level | $308.71 | $136.31 |
| Resistance Level | $327.35 | $138.74 |
| Average True Range (ATR) | 5.48 | 3.41 |
| MACD | 0.28 | -0.04 |
| Stochastic Oscillator | 56.27 | 29.39 |
Clean Harbors Inc is an environmental and industrial services provider that provides parts cleaning and related environmental services to commercial, industrial, and automotive customers. Its business segments are Environmental Services and Safety-Kleen Sustainability Solutions. Environmental Services includes waste collection, transportation, treatment, recycling, and disposal, along with industrial maintenance services. Safety-Kleen Sustainability Solutions provides used oil collection and manufactures base oil, vacuum gas oil, and lubricants. The company generates the majority of its revenues from the Environmental Services segment and operates in the United States, with maximum revenue, and Canada.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.